Literature DB >> 3687878

Clonidine and naltrexone in the outpatient treatment of heroin withdrawal.

H D Kleber1, M Topazian, J Gaspari, C E Riordan, T Kosten.   

Abstract

Clonidine hydrochloride (an alpha-2 adrenergic agonist) and naltrexone hydrochloride (an opioid antagonist), given in combination, provided a safe and effective treatment of abrupt opioid withdrawal over 5 days in an outpatient/day setting. Before starting the clonidine, a naloxone challenge test was used to verify and quantify opioid dependence, and the naloxone challenge test score was then used to determine initial medication doses. Initial naloxone challenge test scores predicted subsequent patient discomfort during the 5-day clonidine-naltrexone protocol. Twelve of 14 (86%) heroin users successfully withdrew from opioids and simultaneously initiated naltrexone maintenance.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3687878     DOI: 10.3109/00952998709001497

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN: 0095-2990            Impact factor:   3.829


  12 in total

1.  Hypocretin receptor 2 antagonism dose-dependently reduces escalated heroin self-administration in rats.

Authors:  Brooke E Schmeichel; Estelle Barbier; Kaushik K Misra; Candice Contet; Joel E Schlosburg; Dimitri Grigoriadis; John P Williams; Camilla Karlsson; Caleb Pitcairn; Markus Heilig; George F Koob; Leandro F Vendruscolo
Journal:  Neuropsychopharmacology       Date:  2015-03-13       Impact factor: 7.853

2.  Ambulatory opiate detoxification and primary care: a role for the primary care physician.

Authors:  P G O'Connor; M E Waugh; R S Schottenfeld; I A Diakogiannis; B J Rounsaville
Journal:  J Gen Intern Med       Date:  1992 Sep-Oct       Impact factor: 5.128

3.  Drug addicts and the GP.

Authors:  C Brewer
Journal:  Br Med J (Clin Res Ed)       Date:  1988-05-21

4.  Escalation patterns of varying periods of heroin access.

Authors:  Leandro F Vendruscolo; Joel E Schlosburg; Kaushik K Misra; Scott A Chen; Thomas N Greenwell; George F Koob
Journal:  Pharmacol Biochem Behav       Date:  2011-03-23       Impact factor: 3.533

5.  Primary care-based ambulatory opioid detoxification: the results of a clinical trial.

Authors:  P G O'Connor; M E Waugh; K M Carroll; B J Rounsaville; I A Diagkogiannis; R S Schottenfeld
Journal:  J Gen Intern Med       Date:  1995-05       Impact factor: 5.128

6.  Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence.

Authors:  Wilfrid Noel Raby; Kenneth M Carpenter; Jami Rothenberg; Adam C Brooks; Huiping Jiang; Maria Sullivan; Adam Bisaga; Sandra Comer; Edward V Nunes
Journal:  Am J Addict       Date:  2009 Jul-Aug

Review 7.  Opioid dependence treatment: options in pharmacotherapy.

Authors:  Angela L Stotts; Carrie L Dodrill; Thomas R Kosten
Journal:  Expert Opin Pharmacother       Date:  2009-08       Impact factor: 3.889

Review 8.  Treatment of heroin (diamorphine) addiction: current approaches and future prospects.

Authors:  Gerardo Gonzalez; Alison Oliveto; Thomas R Kosten
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  Very low dose naltrexone addition in opioid detoxification: a randomized, controlled trial.

Authors:  Paolo Mannelli; Ashwin A Patkar; Kathi Peindl; David A Gorelick; Li-Tzy Wu; Edward Gottheil
Journal:  Addict Biol       Date:  2008-08-19       Impact factor: 4.280

10.  Rewiring of neuronal networks during synaptic silencing.

Authors:  Jana Katharina Wrosch; Vicky von Einem; Katharina Breininger; Marc Dahlmanns; Andreas Maier; Johannes Kornhuber; Teja Wolfgang Groemer
Journal:  Sci Rep       Date:  2017-09-15       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.